Accessibility Menu
Creo Medical Group Plc Stock Quote

Creo Medical Group Plc (LSE: CREO)

$0.10
(-0.3%)
-0.00
Price as of December 4, 2025, 9:13 a.m. ET

KEY DATA POINTS

Current Price
GBX 10.22
Daily Change
(-0.3%) $0.00
Day's Range
GBX 9.90 - GBX 10.25
Previous Close
GBX 10.22
Open
GBX 10.19
Beta
0.05
Volume
462,748
Average Volume
674,795
Market Cap
4.2B
Market Cap / Employee
$10.08M
52wk Range
GBX 9.40 - GBX 22.50
Revenue
-
Gross Margin
-
Dividend Yield
N/A
EPS
GBX 0.00
CAPs Rating
-
Industry
Healthcare Equipment and Supplies

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Creo Medical Group Plc Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
CREO-32.8%-93.86%-42.75%-87%
S&P+13.22%+85.17%+13.11%+203%
Advertisement

Creo Medical Group Plc Company Info

Creo Medical Group Plc operates as a medical device company that focuses on surgical endoscopy. It develops CROMA, an electrosurgical platform that delivers microwave and bipolar radio frequency for precise localized cutting and microwave for controlled coagulation. The company was founded by Mohammed Sabih Chaudhry on September 12, 2016 and is headquartered in Chepstow, the United Kingdom.

News & Analysis

No results found

No news articles found for Creo Medical Group Plc.

Financial Health

General

No data available

No data available for this period.

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

No data available

No data available for this period.

Liabilities

No data available

No data available for this period.

Ratios

No data available

No data available for this period.

Cash Flow

No data available

No data available for this period.

Valuation

MetricYoY Change

No results found

No podcast episodes available.

No results found

No transcripts available.

Advertisement

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.